These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects. González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665 [TBL] [Abstract][Full Text] [Related]
10. Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective. Skundric DS Curr Neurovasc Res; 2005 Oct; 2(4):349-62. PubMed ID: 16181126 [TBL] [Abstract][Full Text] [Related]
11. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. Haegele KF; Stueckle CA; Malin JP; Sindern E J Neuroimmunol; 2007 Feb; 183(1-2):168-74. PubMed ID: 17084910 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. Hellings N; Gelin G; Medaer R; Bruckers L; Palmers Y; Raus J; Stinissen P J Neuroimmunol; 2002 May; 126(1-2):143-60. PubMed ID: 12020966 [TBL] [Abstract][Full Text] [Related]
13. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis. Skundric DS; Cruikshank WW; Drulovic J J Neuroinflammation; 2015 Apr; 12():78. PubMed ID: 25896927 [TBL] [Abstract][Full Text] [Related]
14. Modulatory effect of celastrol on Th1/Th2 cytokines profile, TLR2 and CD3+ T-lymphocyte expression in a relapsing-remitting model of multiple sclerosis in rats. Abdin AA; Hasby EA Eur J Pharmacol; 2014 Nov; 742():102-12. PubMed ID: 25218987 [TBL] [Abstract][Full Text] [Related]
15. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis. Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334 [TBL] [Abstract][Full Text] [Related]
16. The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple Sclerosis. Pappalardo F; Russo G; Pennisi M; Parasiliti Palumbo GA; Sgroi G; Motta S; Maimone D Cells; 2020 Mar; 9(3):. PubMed ID: 32121606 [TBL] [Abstract][Full Text] [Related]
17. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197 [TBL] [Abstract][Full Text] [Related]
18. Computational modeling of the immune response in multiple sclerosis using epimod framework. Pernice S; Follia L; Maglione A; Pennisi M; Pappalardo F; Novelli F; Clerico M; Beccuti M; Cordero F; Rolla S BMC Bioinformatics; 2020 Dec; 21(Suppl 17):550. PubMed ID: 33308135 [TBL] [Abstract][Full Text] [Related]
19. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Ireland SJ; Blazek M; Harp CT; Greenberg B; Frohman EM; Davis LS; Monson NL Autoimmunity; 2012 Aug; 45(5):400-14. PubMed ID: 22432732 [TBL] [Abstract][Full Text] [Related]
20. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. Velez de Mendizabal N; Hutmacher MM; Troconiz IF; Goñi J; Villoslada P; Bagnato F; Bies RR PLoS One; 2013; 8(9):e73361. PubMed ID: 24039924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]